Address
Griffin Court
London, EC1A 9PN
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 3763 7499
Website
Sector
Healthcare
Industry
Biotechnology
Employees
81
First IPO Date
April 25, 1996
| Name | Title | Pay | Year Born |
| Bram Goorden | Chief Executive Officer & Director | 304,000 | 1973 |
| Grant Nash | CFO, COO, Company Secretary & Executive Director | 228,000 | 1976 |
| Derek Lionel Glendon Hill | Co-Founder and President of Regulatory Science & External Relations | 387,006 | 1966 |
| Mark Austin | Chief Technology Officer | 0 | N/A |
| Hannah Esfahanian | HR Manager | 0 | N/A |
| Daniel Rueckert | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| David Hawkes | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Robin Wolz | Chief Scientific Officer | 0 | N/A |
| James Chandler | Chief Business Officer | 0 | N/A |
| Joseph Hajnal | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
IXICO plc, a London-based company established in 1995, specializes in providing data analytics services to the global biopharmaceutical industry. Operating across the UK, Europe (including Switzerland, Netherlands, Ireland), the United States, and internationally, IXICO supports clinical trials by managing the entire lifecycle of study-generated data, from acquisition and processing to in-depth analysis and comprehensive reporting. They leverage proprietary technology platforms like Assessa, a secure digital tool that aids clinical decision-making for patient selection and post-market monitoring, and TrialTracker, which streamlines intricate imaging workflows, handling everything from initial image uploads and quality control to expert analysis, interpretation, and final data delivery within clinical research. IXICO's expertise is concentrated on neurological disorders, including Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating conditions, Progressive Supranuclear Palsy, and various rare neurological diseases. Their services encompass not only the collection, optimization, and analytics for rare neurological disorders but also drug development analytics, specialized imaging operations, post-market surveillance support, and expert consultancy. The company delivers comprehensive, end-to-end services for clinical trials, covering initial trial design and consultation, meticulous project management, imaging site setup and management, robust data management, expert image reading and analysis, and guidance on regulatory pathways.